Translation
Notice: This document is an excerpt translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

December 12, 2024

To whom it may concern,

Company name:	Heartseed Inc.
Representative:	Keiichi Fukuda, MD/PhD/FACC, CEO, Representative Director of the Board
Securities code:	219A, Tokyo Stock Exchange
Inquiries:	Mutsuki Takano, CFO, Director of the Board TEL: +81-(0)3-6665-8068 (IR)

Notice Regarding the Progress of Phase 1/2 Clinical Trial (LAPiS Study)

Heartseed Inc. (the "Company") hereby announces that total 9 patients (5 patients for low-dose cohort and 4 patients for high-dose cohort) were dosed in the LAPiS study as of December 12, 2024. The patient enrollment will be completed by dosing another 1 patient in the high-dose cohort, which will be released after its completion, accordingly. On December 18, 2024, Heartseed will conduct the investors call (Japanese language only) about the financial results for the fiscal year ended October 31, 2024, including the clinical trial progress reported in this release.

(Cautionary notice on forward-looking information)

The financial results forecasts and other forward-looking information contained in this document are based on the information currently available to the Company and certain assumptions considered reasonable by the Company. It is not a guarantee that the forecasts will be achieved, and actual results may differ significantly from such forecasts depending on various factors.